Tempus AI, Inc. (NASDAQ:TEM) CEO Eric P. Lefkofsky Sells 187,655 Shares

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric P. Lefkofsky sold 187,655 shares of the stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $37.54, for a total value of $7,044,568.70. Following the sale, the chief executive officer now directly owns 9,557,283 shares in the company, valued at $358,780,403.82. This trade represents a 1.93 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Tempus AI Stock Performance

TEM traded up $2.51 during trading on Friday, reaching $35.54. 5,785,145 shares of the company’s stock were exchanged, compared to its average volume of 1,582,344. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. Tempus AI, Inc. has a 1 year low of $22.89 and a 1 year high of $79.49. The stock has a fifty day moving average of $51.70.

Institutional Trading of Tempus AI

A number of hedge funds and other institutional investors have recently made changes to their positions in TEM. Kovitz Investment Group Partners LLC acquired a new position in Tempus AI in the third quarter valued at approximately $1,367,000. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Tempus AI by 1,591.2% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after purchasing an additional 1,145,698 shares in the last quarter. Captrust Financial Advisors acquired a new position in shares of Tempus AI in the 3rd quarter valued at $2,726,000. Sigma Planning Corp purchased a new stake in Tempus AI during the third quarter worth $1,323,000. Finally, Dakota Wealth Management acquired a new stake in Tempus AI during the third quarter valued at $1,185,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on TEM. Wolfe Research initiated coverage on shares of Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target on the stock. Loop Capital boosted their target price on Tempus AI from $48.00 to $57.00 and gave the stock a “buy” rating in a research note on Tuesday, October 15th. Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and increased their price target for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Bank of America boosted their price target on Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research note on Friday, December 13th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $70.00 price objective (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $56.00.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.